Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
Selection of the right cancer treatment is still a challenge. Here, the authors introduce a framework to analyze treatment benefits, using the idea that patients with similar genetic tumor profiles receiving different treatments can be used to model their responses to the alternative treatment.
Guardado en:
Autores principales: | Joske Ubels, Pieter Sonneveld, Erik H. van Beers, Annemiek Broijl, Martin H. van Vliet, Jeroen de Ridder |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bc84203d4d9b4efaa0dbb9de2ebf654a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
por: Mirian Brink, et al.
Publicado: (2021) -
Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu YC, et al.
Publicado: (2014) -
The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma
por: Georgia Stewart, et al.
Publicado: (2021) -
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
por: Meletios A. Dimopoulos, et al.
Publicado: (2021) -
Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Fatih M. Uckun, et al.
Publicado: (2021)